Stock Market

Nomura has a buy on Dr Reddy’s Labs, target price Rs 3,200

   Download Android App    Share in      FullScreen   CheckVideos

Nomura has a buy rating on Dr Reddy’s Laboratories in the long term with a target price of Rs 3,200.

Shares of Dr Reddy’s Laboratories ended down 0.2% at Rs 2,816.25 on Monday while BSE Sensex closed 70.99 points down at 40,938.72. Company FinancialsFor the quarter ended 30-09-2019, the company has reported consolidated sales of Rs 4800.80 crore, up 24.90% from last quarter sales of Rs 3843.60 crore and up 30.22 % from last year same quarter sales of Rs 3686.60 crore.

The company has reported net profit after tax of Rs 1095.10 crore in the latest quarter.

The company’s top management includes Dr.Bruce L A Carter, Mr.Allan Oberman, Mr.Bharat N Doshi, Mr.G V Prasad, Mr.K Satish Reddy, Mr.Leo Puri, Mr.Prasad R Menon, Mr.Sridar Iyengar, Ms.Kalpana Morparia, Ms.Shikha Sharma.

Company has S R Batliboi - Associates LLP as its auditors.

As on 30-09-2019, the company has a total of 166,145,748 shares outstanding.

Investment RationaleAmneal is the first generic company to receive approval for a generic version of Nuvaring, said Nomura.

Dr Reddy’s and Teva are the other known filers, it said.

Amneal will have first-mover advantage; hence, the upside for Dr Reddy’s is likely to be curtailed to an extent, it said.




Unlimited Portal Access + Monthly Magazine - 12 issues-Publication from Jan 2021

Buy Our Merchandise (Peace Series)

 

Contribute US to Start Broadcasting


It's Voluntary! Take care of your Family, Friends and People around You First and later think about us. Its Fine if you dont wish to contribute and if you wish to contribute then think about the Homeless first and Feed them. We can survive with your wishes too :-). You can Buy our Merchandise too which are of the finest quality.

Debit/Credit/UPI

UPI/Debit/Credit

Paytm

STRIPE

Details
Category: Stock Market


21